Trogarzo

ibalizumab (IBA)

For people lacking sufficient treatment options; see “More information” section below
Entry Inhibitor

Standard Dose

Administered once every two weeks via intravenous infusion. Treatment begins with an IV loading (starting) dose of 2,000 mg, followed by an 800 mg IV infusion maintenance dose given every two weeks thereafter. Must be taken in combination with another antiretroviral(s).

The first infusion takes at least 30 minutes. If no infusion-related adverse events occur, subsequent infusions take 15 minutes. Doses may be administered every two weeks at an inpatient and/or outpatient setting, including at-home infusion, if desired. All patients should be observed for 1 hour after completing first infusion. If no infusion-associated adverse reaction is noted, the post-infusion observation time can be reduced to 15 minutes. Must be given with an optimized background regimen (OBR). An OBR consists of the best antiretroviral therapy that can be made for each patient based on the patterns of HIV drug resistance in their virus. Dose modifications of Trogarzo are not required when administered with any other antiretroviral or any other treatments.

If a maintenance dose of Trogarzo is missed by 3 days or longer beyond the scheduled dosing day, a loading dose (2,000 mg) should be administered as early as possible. Then resume maintenance dosing (800 mg) every 14 days thereafter.



Manufacturer

Theratechnologies Inc.
theratech.com
trogarzo.com


AWP

$2,724.00 per vial; 10 vials for loading dose and two vials for continuing dose (every two weeks)

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments